On January 27th, Lu Xiaochun, Chairman of Shanghai Municipal Commission of Economy and Informatization, visited Shanghai Op Biomedical Co., Ltd for research. The team visited the exhibition hall of the company, listened to the company's introduction, and paid a visit to the leading talents of the company.
Mr. Lu affirmed the achievements of the company in the development and industrial promotion of the integration of real-time detection and rapid diagnostic reagents and instruments around the development orientation of the biomedical industry. He hoped that the company will focus on the goal of building a biomedical industrial cluster in Shanghai during the "14th five-year plan" period, expand and strengthen its main business, have its own "fist products" from R & D to achievement transformation, and constantly activate new impetus for high-quality development. It is important to firmly grasp scientific and technological innovation as the first driving force of enterprise development, firmly stand at the front end of the field of real-time detection, rely on intelligent and data-based means, increase innovation and breakthrough, create "inclusive products" and make more contributions to the people. What's more, it is necessary to give full play to the advantages of talents as the first resource, continue to build excellent talent teams, vigorously carry forward the spirit of scientists and entrepreneurship, and cultivate more discipline leaders and high-level industrial talents. The Commission will pay close attention to the growth of enterprises as always, and actively do a good job in service guarantee for enterprise production, operation and talent cultivation.
Shanghai Op Biomedical Co., Ltd., established in 1997, is a high-tech enterprise focusing on medical intelligent diagnosis. The company has the first mover advantage in the detection of inflammatory infection and infectious diseases. It has built a R&D technology platform with latex immunoturbidimetry, fluorescence immunochromatography and colloidal gold method as the core, integrated the automation technology of real-time detection products, whole blood sample detection and correction technology, and large data collection technology, and developed the clinical application of new markers, the automatic detection of traditional markers, product information data analysis and a series of products that can meet the needs of medical institutions at all levels.
